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Introduction: Central venous saturation (ScvO2) monitoring has been suggested to address the issue of adequate
cardiocirculatory function in the context of cardiac surgery. The aim of this study was to determine the impact of
low (L) (<60%), normal (N) (60%-80%), and high (H) (>80%) ScvO2 measured on intensive care unit (ICU) admission
after cardiac surgery.
Methods: We conducted a retrospective, cross-sectional, observational study at three ICUs of a university hospital
department for anaesthesiology and intensive care. Electronic patient records of all adults who underwent cardiac
surgery between 2006 and 2013 and available admission measurements of ScvO2 were examined. Patients were
allocated to one of three groups according to first ScvO2 measurement after ICU admission: group L (<60%), group
N (60%-80%), and group H (>80%). Primary end-points were in-hospital and 3-year follow-up survival.
Results: Data from 4,447 patients were included in analysis. Low and high initial measurements of ScvO2 were
associated with increased in-hospital mortality (L: 5.6%; N: 3.3%; H: 6.8%), 3-year follow-up mortality (L: 21.6%;
N: 19.3%; H: 25.8%), incidence of post-operative haemodialysis (L: 11.5%; N: 7.8%; H: 15.3%), and prolonged hospital
length of stay (L: 13 days, 9–22; N: 12 days, 9–19; H: 14 days, 9–21). After adjustment for possible confounding
variables, an initial ScvO2 above 80% was associated with adjusted hazard ratios of 2.79 (95% confidence interval (CI)
1.565-4.964, P <0.001) for in-hospital survival and 1.31 (95% CI 1.033-1.672, P = 0.026) for 3-year follow-up survival.
Conclusions: Patients with high ScvO2 were particularly affected by unfavourable outcomes. Advanced
haemodynamic monitoring may help to identify patients with high ScvO2 who developed extraction dysfunction
and to establish treatment algorithms to improve patient outcome in these patients.Introduction
Postoperative mortality and morbidity of surgical pa-
tients are still unsolved puzzles for the clinician [1]. In a
multicentre study, the rates of death for patients who
underwent surgery varied substantially across hospitals.
A recent European study confirmed these results [2,3].
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unless otherwise stated.for the surgical patient. Worldwide, routine care began
including goal-directed optimization in the perioperative
period to avoid hypoperfusion and secondary organ
failure. According to recent meta-analyses, this strategy
showed improved outcomes in the cohort of optimized
patients [4]. Nevertheless, this approach will be success-
ful only if the haemodynamic goal still holds.
Cardiac surgery has been shown to be a life-saving
procedure in a selected group of patients with coronary
heart disease and valve dysfunction [5]. However, this
procedure carries a significant risk of death and major
complications. In recent years, there has been substantialThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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decreasing the risk for unfavourable outcomes in this
group of patients [6,7]. One major step forward was the
adoption of early goal-directed, evidence-based haemo-
dynamic treatment strategies in cardiac surgery patients
[6]. Goal-directed administration of perioperative fluids
has been shown to guarantee the best possible optimiza-
tion of volume therapy in these patients [8]. Several
single-centre studies and meta-analyses have shown im-
proved outcomes by using additional haemodynamic
parameters to adjust individual therapy in the periopera-
tive setting [4] of general and cardiac surgery. In cardiac
surgery patients in particular, cardiac dysfunction must
be detected as early as possible to facilitate adequate
therapy using positive inotropic drugs as well as fluids
and vasodilators [8].
Central venous saturation (ScvO2) monitoring has been
suggested as one goal to address the issue of adequate
cardio-circulatory function in the context of cardiac sur-
gery [6]. This parameter seems especially attractive as
venous saturation is readily measurable without add-
itional monitoring technology and is an excellent indica-
tor of the match/mismatch between cardiac output,
arterial oxygen saturation, and haemoglobin level as de-
terminants of both oxygen delivery and oxygen con-
sumption. Several studies in the cardiac-surgery patient
population and in other surgical specialties have shown
that low ScvO2 and mixed venous saturation (SvO2) are
associated with unfavourable outcomes [9,10]. In addi-
tion, high venous saturation has been shown to be asso-
ciated with increased complication rates in emergency
room patients, intensive care unit (ICU) patients, and
cardiac-surgery patients [11-13]. However, the results of
these studies may be biased by the small number of pa-
tients. The aim of this retrospective cross-sectional
study, therefore, was to investigate the impact of low,
normal, and high ScvO2 on postoperative mortality and
organ dysfunction in a large cardiac surgery ICU data-
base that reported data from three distinct ICUs at our
institution.
Methods
With the written consent of the federal data protection
officer and the hospital ethics commission (ethics com-
mittee - Charité - Universitätsmedizin Berlin, EA1/034/
13), clinical routine data from all patients who underwent
cardiac surgery between 2006 and 2013 were extracted
from the two electronic patient data management systems
at our hospital (COPRA System, Sasbachwalden, Germany,
and SAP, Walldorf, Germany) into an anonymized study
database. Individual patient consent was waived by the
ethics commission. Cardiac surgery was defined as a docu-
mented procedure on valves or vessels in proximity to the
heart or coronary vessels. Cardiopulmonary bypass andanaesthesia management were performed in accordance
with the department’s standard operating procedures de-
scribed in detail elsewhere [14]. Haemodynamic optimiza-
tion was continuously accomplished in accordance with
the German guidelines [6].
To be included in our study, patients had to be admit-
ted postoperatively to one of our three ICUs serving
postoperative cardiac surgery patients. Patients who
were under the age of 18 by the time of surgery or who
had a pulmonary artery catheter were excluded. Patients
were grouped on the basis of first measurement of ScvO2
after ICU admission as low, normal, or high according
to a normal range defined as 60% to 80%. ScvO2 in the
ICU was determined by point-of-care blood gas analysis
(ABL800 FLEX; Radiometer, Copenhagen, Denmark).
Mortality, length of stay, time of ventilation, renal dys-
function, and days without organ failure were defined as
outcome criteria. Information on long-term mortality,
defined as 3 years after ICU admission, was acquired,
with clearance from the federal data safety officer, by
consulting the registry office in Berlin, Germany. Pa-
tients with shorter observation intervals (that is, less
than 3 years between ICU admission and the date of
inquiry at the registry office) were excluded in analyses
of long-term mortality. Renal dysfunction was evaluated
in accordance with the creatinine criteria of the KDIGO
(Kidney Disease: Improving Global Outcomes) clinical
practice guidelines for acute kidney injury [15]. Patients
with pre-operative haemodialysis were excluded in ana-
lysis on renal outcome parameters. Days of organ failure
were assessed in accordance with the criteria of the Se-
quential Organ Failure Assessment score with a toler-
ance of 1 point in each category (respiration: partial
pressure of oxygen/fraction of inspired oxygen (PaO2/
FiO2) of less than 300; circulation: use of epinephrine or
norepinephrine; central nervous system: Glasgow Coma
Scale score of less than 13; bilirubin of at least 2.0 mg/
dL; kidneys: serum creatinine of at least 2.0 mg/dL).
To control for possible confounding variables, we
assessed the risk of cardiac surgery by using the Age, Cre-
atinine, and Ejection Fraction (ACEF) risk score by
Ranucci et al. [16] and post-operative ICU admission
scores—Acute Physiology And Chronic Health Evaluation
II (APACHE II) and Therapeutic Intervention Scoring
System (TISS)—in addition to basic patient characteristics.
The design of this observational cohort study and the re-
sults are reported in accordance with the STROBE
(Strengthening the Reporting of Observational Studies in
Epidemiology) statement [17].
Statistical analysis
Descriptive analyses and statistical testing were per-
formed by using the R Project of Statistical Computing
3.0.1. When normal distribution was ruled out by using
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median and interquartile range (IQR) or as mean ±
standard deviation. Qualitative observations were char-
acterized by numbers and percentages. Statistical signifi-
cance among groups was analysed univariately with the
exact non-parametric Kruskal-Wallis test and (pair-wise)
with the exact Mann–Whitney U test. Exact chi-squared
tests were used for qualitative data. Correlations were
evaluated by using Spearman’s correlation coefficient.
Survival was analysed by using Kaplan-Meier estimations
and tested by the log-rank test between groups. Multi-
variate analysis tested for factors influencing survival.
For that purpose, all pre-operative variables, ICU admis-
sion scores, and cumulative dosages (first 24 hours in the
ICU) of inotropic drugs that showed significant P values
in univariate Cox regression were included (besides the
grouping) in multivariate Cox regression analyses with
stepwise backwards selection. Clinical outcomes with re-
spect to time were analysed by using a non-parametric
analysis of longitudinal data in a two-factorial design (first
factor: groups; second factor: time). A two-tailed P value
of less than 0.05 was considered statistically significant.
All tests should be understood as constituting explorative
analysis; no adjustment for multiple testing has been
made.
Results
In this retrospective analysis, data from 6,909 patients
who underwent cardiac surgery between January 2006
and December 2013 were analysed. There were no re-
cords for ScvO2 in 1,735 patients, and 697 patients re-
ceived a pulmonary artery catheter. Both resulted in
exclusion from the study, leaving a total of 4,477 patientsFigure 1 CONSORT (Consolidated Standards Of Reporting Trials) diag
group who were included in analyses, the parenthesis present the number
artery catheter; ScvO2, central venous saturation.for analysis. For sub-analysis on long-term survival,
complete follow-up data were available for 2,138 patients
(Figure 1). In all patients, median ScvO2 was 72.2 (IQR
65.5-78.5) with a standard deviation of 9.9 and was mea-
sured, on average, within 157 minutes (IQR 81–366)
after admission to the ICU.
In 499 patients, ScvO2 was less than 60% (group L), in
3,064 patients ScvO2 was between 60 and 80% (group N),
and in 914 patients ScvO2 was more than 80% (group H)
at admission to the ICU after cardiac surgery.
Demographic and surgery-related data are shown in
Table 1. Patients with low ScvO2 were slightly older than
patients from the other two groups. Patients from group
H had significantly lower body mass index compared
with the other two groups. The predominant type of sur-
gery was coronary artery bypass graft surgery in all three
groups. Duration of anaesthesia and surgery did not dif-
fer significantly among groups. APACHE II and TISS
scores were significantly higher in group H compared
with reference group N; however, the slight difference
(not more than 1 point) might not be considered clinic-
ally relevant. Patients from group H presented a signifi-
cantly increased ACEF score. Patients from group H
were significantly less frequently diagnosed with coron-
ary heart disease compared with those from group N.
Also, patients from group H were significantly more fre-
quently diagnosed with atrial fibrillation and chronic
renal insufficiency than patients from the reference
group (Table 1).
Patients from group H had the highest in-hospital
mortality (6.8%), compared with 5.6% in the group with
low ScvO2 and 3.3% in group N (Table 2). Three-year
follow-up data were available for 3,517 out of 4,477ram. In the last three boxes containing the number of patients per
of patients with complete 3-year follow-up data. PAC, pulmonary
Table 1 Patient characteristics
Group L Group N Group H Number
N = 499 N = 3,064 N = 914
Basic data
Age, years 71.0* (64.0–75.0) 69.0 (61.0–75.0) 69.0 (61.0–75.0) 4,477
Sex: Female 149 (29.9%) 862 (28.1%) 264 (28.9%) 4,477
Body mass index 27.4 (24.5–30.6) 27.0 (24.4–30.4) 26.4* (23.7–29.6) 3,202
Surgery
Type of surgery * * 4,477
CABG 290 (58.1%) 1821 (59.4%) 441 (48.2%)
Valves 129 (25.9%) 891 (29.1%) 367 (40.2%)
Both 80 (16.0%) 352 (11.5%) 106 (11.6%)
Duration of anesthesia, minutes 290 (245–335) 290 (240–335) 285 (235–330) 3,344
Duration of surgery, minutes 202 (165–245) 200 (160–240) 190 (155–240) 3,594
Pre-op risk assessment (ACEF) 1.28 (1.14–1.54) 1.27 (1.12–154) 1.43* (1.20–1.98) 2,377
Scores on ICU admission
APACHE II 18.0 (14.0–24.0) 18.0 (14.0–24.0) 19.0* (14.0–25.0) 4,008
TISS28 36.0 (33.0–39.0) 36.0 (33.0–39.0) 36.0* (33.0–40.0) 4,456
Pre-existing medical conditions
Coronary heart disease 407 (81.6%) 2392 (78.1%) 662* (72.4%) 4,477
COPD 79 (15.8%) 526 (17.2%) 172 (18.8%) 4,477
Diabetes mellitus 208 (41.7%) 1,205 (39.3%) 369 (40.4%) 4,477
Peripheral vascular disease 97 (19.4%) 611 (19.9%) 197 (21.6%) 4,477
Atrial fibrillation 151 (30.3%) 859 (28.0%) 326* (35.7%) 4,477
Chronic renal insufficiency 118 (23.6%) 696 (22.7%) 309* (33.8%) 4,477
Values are presented as number (percentage) or as median (interquartile range). Significant group differences are displayed as asterisks in columns for groups
L (low) and H (high) with reference to group N (normal). ACEF, Age, Creatinine, and Ejection Fraction; APACHE II, Acute Physiology And Chronic Health Evaluation
II; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; TISS28, Therapeutic Intervention Scoring System 28.
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because the interval between surgery and the retrospect-
ive data collection was less than 3 years. Results for 3-
year follow-up mortality show a similar distribution
among groups as in-hospital mortality with 19.3% for
group N, 21.6% for group L, and 25.8% for group H.
Lengths of hospital stay, ICU stay, and postoperative
ventilation were significantly longer in patients from
group H compared with patients from group N. Patients
from group H also had the highest rate of renal dysfunc-
tion. In keeping with that finding, the incidence of post-
operative need for renal replacement therapy (RRT) was
15.3% in patients with ScvO2 above 80% compared with
9.4% in group N and 13.2% in group L (Table 2). To rule
out the time of admission as a confounder for prolonged
ventilation, we compared the hours of admission as a
binary variable (that is, 8 to 19 versus 20 to 27 hours).
No significant difference was found among groups. Out-
come parameters are reported separately with respect to
the type of surgery that was performed (that is, coronaryartery bypass graft, valves, or both) in Additional file 1:
Tables S2a-c of the electronic supplement.
In Figure 2, in-hospital mortality in pre-specified sub-
sets of initial ScvO2 measurements is shown. There is a
U-shaped relationship between initial ScvO2 and mortal-
ity, showing highest mortality for patients with ScvO2
below 60% and above 80%.
In regard to the use of inotropic medication during
the first 24 hours after surgery, patients from group H re-
ceived epinephrine more frequently and received enoxi-
mone with respectively higher dosages (Table 3).
Patients of group H had significantly elevated levels of
lactate, blood glucose, leukocyte count, and procalcito-
nin (PCT) as inflammation markers in the immediate
period after surgery (Table 4). Creatinine, international
normalized ratio, and creatine kinase MB also showed
elevated levels in patients of group H. The calculated
oxygen extraction rate ranged from 0.15 (IQR 0.12-0.17)
in group H to 0.42 (IQR 0.41-0.46) in group L (Pgroups
<0.001 in non-parametric longitudinal analyses). For the
Q12
Table 2 Selected outcome parameters
Group L Group N Group H Number
N = 499 N = 3,064 N = 914
General outcome measures
Mortality (in-hospital) 28* (5.6%) 102 (3.3%) 62* (6.8%) 4,477
Mortality (3-year follow-up) 60 (21.6%) 276 (19.3%) 111* (25.8%) 2,138
LOS (hospital), days 13.0* (9.00–22.0) 12.0 (9.00–19.0) 14.0* (9.00–21.0) 4,477
LOS (ICU), days 6.0* (4.0–9.0) 5.0 (3.0–8. 0) 6.0* (4.0–100) 4,477
Time of ventilation, hours 9.0 (6.0–16.0) 8.0 (5.0–15.0) 12.0* (7.0–21.0) 4,296
KDIGO * * 4,165
Stage 0 324 (70.4%) 2288 (79.4%) 589 (71.5%)
Stage 1 75 (16.3%) 302 (10.5%) 86 (10.4%)
Stage 2 9 (2.0%) 49 (1.7%) 20 (2.4%)
Stage 3 52 (11.3%) 242 (8.4%) 129 (15.7%)
KDIGO Stages 1-3 136* (29.6%) 593 (20.6%) 235* (28.5%) 4,165
Incidence of haemodialysis 56* (11.5%) 235 (7.82%) 130* (15.3%) 4,344
Mean percentage of days in the ICU without organ failure
Respiration 58.0%* 64.1% 62.7% 4,477
Liver 98.3% 98.6% 97.8% 4,477
Circulation 48.3%* 55.2% 50.0%* 4,477
Central nervous system 80.1% 83.0% 80.5% 4,477
Kidneys 84.7%* 88.9% 84.4%* 4,344
Values are presented as number (percentage) or as median (interquartile range). Significant group differences are displayed as asterisks in columns for groups
L (low) and H (high) with reference to group N (normal). Renal dysfunction was assessed in accordance with the KDIGO (Kidney Disease: Improving Global
Outcomes) classification, calculating the change in serum creatinine from pre-op until postoperative day 7. Days of organ failure were calculated according to the
criteria of the Sequential Organ Failure Assessment score. Respiration: partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) of less than 300; bilirubin
of at least 2.0 mg/dL; circulation: use of epinephrine or norepinephrine; central nervous system: Glasgow Coma Scale score of less than 13; kidneys: serum creatinine
of at least 2.0 mg/dL. Patients with pre-operative haemodialysis (n = 133) were excluded from analysis of renal outcome parameters. ICU, intensive care unit; LOS,
length of stay.
Figure 2 In-hospital mortality for specified ranges of central
venous saturation (ScvO2). Mortality is highest for venous saturations
below 60% and above 80% with a trough between 60% and 80%.
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basic monitoring, please see Additional file 1: Table S1
in the electronic supplement.
To evaluate multivariately the association of ScvO2 with
survival, all pre-operative variables, ICU admission scores,
and cumulative dosages (first 24 hours in the ICU) of ino-
tropic drugs that showed significant P values in univariate
Cox regression were included (besides grouping) in multi-
variate Cox regression analyses (Table 5). Compared with
reference group N, patients from group H had an almost
threefold risk of dying in hospital (hazard ratio 2.79, 95%
confidence interval (CI) 1.565-4.964, P <0.001). The
hazard ratio of group H (compared with N) for 3-year
follow-up survival was 1.31 (95% CI 1.033-1.672, P =
0.026). When the incidence of pre-operative haemodialysis
was included in the regression model as additional ex-
planatory variable, the previously calculated hazard ratios
did not change substantially. However, the regression
model’s quality decreased. Kaplan-Meier curves for 3-year
follow-up survival are shown in Figure 3. To investigate
whether extraction dysfunction (that is, high ScvO2) could
be predicted by a patient’s comorbidities, we developed
Table 3 Inotropic medication on postoperative day one
Group L Group N Group H Number
N = 499 N = 3,064 N = 914
Norepinephrine
Frequency 275 (55.1%) 1,790 (58.4%) 683* (74.7%) 4,477
Dosage, mg/24 hours 1.17 (0.33–3.30) 1.11 (0.26–4.08) 2.20* (0.52–6.58) 2,748
Epinephrine
Frequency 63 (12.6%) 427 (13.9%) 384* (42.0%) 4,477
Dosage, mg/24 hours 0.51* (0.25–2.66) 1.35 (0.43–3.23) 1.82* (0.64–4.13) 874
Dobutamine
Frequency 317* (63.5%) 2,106 (68.7%) 486* (53.2%) 4,477
Dosage, mg/24 hours 227* (121–382) 190 (85.1–321) 134* (53.1–266) 2,909
Enoximone
Frequency 84* (16.8%) 324 (10.6%) 229* (25.1%) 4,477
Dosage, mg/24 hours 173 (75.4–265) 185 (92.7–294) 222* (127–305) 637
Levosimendan
Frequency 4 (0.80%) 23 (0.75%) 17* (1.86%) 4,477
Dosage, mg/24 hours 5.79 (3.55–8.11) 7.74 (2.85–9.66) 8.50 (5.37–9.38) 44
Values are presented as number (percentage) or as median (interquartile range). Significant group differences are displayed as asterisks in columns for groups L
(low) and H (high) with reference to group N (normal). When a patient was discharged or was deceased during postoperative day 1, displayed dosages were
normalized to 24 hours.
Balzer et al. Critical Care  (2015) 19:168 Page 6 of 12another regression model. However, no significant effect
was found (P >0.05, data not shown).
Discussion
In this study, we report haemodynamic and outcome
data from a large database including data from three dif-
ferent ICUs serving postoperative cardiac surgery pa-
tients. The most important findings of this study were
that patients with a presumed ‘safe’ initial ScvO2 above
80% had the highest in-hospital mortality and the highest
mortality in 3-year follow-up. Additionally, these patients
showed increased length of mechanical ventilation, a
higher incidence of renal dysfunction including increased
rate of RRT, evidence of severe postoperative inflamma-
tion indicated by increased leukocyte counts and PCT
levels, and prolonged lengths of ICU and hospital stay
compared with patients with a ‘normal’ ScvO2 (60%
to 80%). In the multivariate analysis, patients from group
H had an almost threefold risk of dying in hospital and
a 1.3 ratio for 3-year follow-up survival compared with
group N.
Patients in the high ScvO2 group differed from the
other ScvO2 groups with respect to the type of surgery
and the pre-operative ACEF score and more frequently
received inotropic and vasoactive drugs. Also, the
patients in the high ScvO2 group had more frequent
atrial fibrillation as a complication diagnosis. Thus, it
was (per se) not astonishing that these patients also hada higher morbidity and mortality. Based on the classic
pathophysiological concept, low levels of ScvO2 or SvO2
are reflective of tissue hypoperfusion and associated with
higher complication rates [18]. Our finding that patients
with a seemingly ‘safe’ ScvO2 above 80% showed even
worse outcome is in clear contrast to previous studies.
Pre-existing chronic haemodialysis with arterial-
venous shunts is known to lead to increased venous
saturation. Therefore, a possible explanation for un-
favourable outcome in group H could be this bias as
patients with chronic renal failure are known to have
an inferior outcome after surgery, including cardiac
surgery. However, for this study cohort, this is not
the explanation for the observed outcomes in group
H as including incidence of pre-operative haemodialy-
sis with arterial-venous shunts did not result in sub-
stantial changes of previously calculated hazard ratios.
Interestingly, the high ScvO2 group also presented with
significantly increased plasma lactate levels. It is well ac-
cepted that increased lactate levels are associated with
increased mortality after cardiac surgery [19]. Further-
more, it is of note that a recent retrospective study re-
vealed a link between elevated lactate levels during
normal or even high ScvO2 and unfavourable outcome
[20]. In that study with 629 patients, elevated lactate
levels in the setting of a normal ScvO2 were associated
with significantly higher incidence of major complica-
tions. However, high lactate levels not only may be
Table 4 Postoperative laboratory data
Group L Group N Group H Number
N = 499 N = 3,064 N = 914
Lactate, mg/dL *
0–6 hours 15.0 (10.0-21.0) 15.0 (10.0-22.0) 22.0* (12.0-50.8) 4,188
6–12 hours 14.0 (10.0-20.0) 14.0 (10.0-21.0) 16.0* (10.0-26.0) 4,254
12–18 hours 11.0 (9.00-15.0) 11.0 (9.00-16.0) 12.0* (9.00-17.0) 4,274
18–24 hours 12.0 (9.00-16.0) 12.0 (9.00-16.0) 12.0 (9.00-16.0) 4,335
Blood glucose, mg/dL *
0–6 hours 142* (123–164) 148 (129–169) 152* (126–184) 4,188
6–12 hours 132* (117–149) 135 (119–153) 137* (119–158) 4,254
12–18 hours 128 (112–146) 131 (116–146) 129 (112–148) 4,254
18–24 hours 136 (118–156) 137 (120–157) 135 (118–158) 4,335
Haemoglobin, g/dL *
POD 0 10.0* (9.30-10.8) 10.3 (9.50-11.1) 10.3 (9.50-11.3) 4,350
POD 1 9.70 (9.10-10.4) 9.70 (9.00-10.5) 9.80 (9.10-10.6) 4,477
POD 2 9.60 (9.10-10.4) 9.70 (9.00-10.4) 9.70 (9.10-10.4) 4,477
POD 3 9.70 (9.20-10.5) 9.80 (9.20-10.6) 9.80 (9.20-10.6) 4,477
Leukocytes, /nL *
POD 0 12.0 (9.48-15.4) 12.4 (9.75-15.5) 13.2* (10.1-16.8) 4,171
POD 1 13.1 (10.7-16.6) 13.8 (11.0-16.7) 14.4* (11.3-17.8) 4,413
POD 2 13.6 (11.0-16.9) 14.0 (11.2-17.1) 14.9* (11.6-18.6) 4,439
POD 3 11.9 (9.27-15.0) 11.6 (9.36-14.4) 12.0* (9.50-15.6) 4,446
Procalcitonin, μg/L *
POD 0 0.48 (0.48-0.49) 0.58 (0.14-1.41) 1.70 (0.27-5.87) 22
POD 1 1.63 (0.39-3.98) 1.80 (0.56-5.28) 4.19* (1.62-11.8) 194
POD 2 1.06 (0.34-4.90) 1.52 (0.40-5.45) 4.37* (1.50-11.9) 562
POD 3 1.00 (0.34-3.27) 0.90 (0.30-3.57) 3.05* (0.80-8.45) 979
Alanine transaminase, U/L *
POD 0 22.0 (16.0-31.0) 22.0 (16.0-33.0) 23.0 (16.0-35.0) 3,999
POD 1 24.0 (17.0-35.0) 23.0 (17.0-35.0) 24.0 (17.0-38.0) 4,336
POD 2 24.0 (18.0-38.0) 24.0 (17.0-35.0) 25.0* (18.0-39.0) 4,389
POD 3 25.5 (18.0-39.0) 24.0 (17.0-36.0) 25.0 (18.0-40.0) 4,401
Creatinine, mg/dL * *
Last preop 1.02* (0.86-1.20) 0.98 (0.83-1.18) 1.08* (0.88-1.35) 4,322
POD 1 1.14* (0.91-1.52) 1.06 (0.86-1.37) 1.19* (0.93-1.73) 4,412
POD 2 1.15* (0.90-1.55) 1.04 (0.82-1.42) 1.20* (0.90-1.77) 4,442
POD 3 1.11* (0.85-1.48) 1.00 (0.80-1.37) 1.16* (0.86-1.70) 4,449
International normalized ratio * *
POD 0 1.31 (1.22-1.43) 1.30 (1.22-1.40) 1.33* (1.23-1.45) 4,153
POD 1 1.27 (1.19-1.37) 1.26 (1.18-1.35) 1.28* (1.20-1.39) 4,412
POD 2 1.26* (1.19-1.37) 1.25 (1.18-1.35) 1.27* (1.19-1.39) 4,437
POD 3 1.24* (1.15-1.34) 1.21 (1.13-1.31) 1.23* (1.14-1.35) 4,445
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Table 4 Postoperative laboratory data (Continued)
Creatine kinase MB, U/L * *
POD 0 38.0* (27.0-55.5) 34.0 (26.0-52.0) 38.0* (26.0-61.0) 3,913
POD 1 33.0* (22.0-56.0) 31.0 (22.0-51.0) 33.0* (22.0-58.0) 4,191
POD 2 27.0* (19.0-46.0) 24.0 (17.0-39.0) 25.0 (17.0-43.0) 4,222
POD 3 23.5* (16.0-38.0) 21.0 (15.0-33.0) 21.0 (15.0-35.0) 4,233
Values are presented as median (interquartile range). Significant group differences are displayed as asterisks in columns for groups L (low) and H (high) with
reference to group N (normal). Significance per category (for example, lactate) with respect to the given groups over time was assessed by using a non-parametric
analysis of longitudinal data in a two-factorial design. POD, postoperative day.
Balzer et al. Critical Care  (2015) 19:168 Page 8 of 12reflective of tissue hypoperfusion (that is, anaerobic me-
tabolism leading to lactic acidosis type A) but also may
be induced by factors stimulating glycogenolysis, glycoly-
sis, and hyperglycemia (that is, lactic acidosis type B). It
is of note that epinephrine is an important trigger for
the latter effects [21] and that the patients in the high
ScvO2 group more frequently received norepinephrine
and epinephrine than the normal and the low ScvO2
groups, suggesting that the hyperlactatemia may be, at
least in part, an effect of catecholamine treatment.
Additionally, as we found a significant higher occur-
rence of epinephrine application in group H, it cannot
be ruled out that the use of epinephrine aggravates the
shunting effects in postoperative cardiac surgery pa-
tients. If so, the question of whether epinephrine is what
we are aiming for or just creates good numbers in the
charts (for example, higher cardiac index and higher
mean arterial pressure) clearly arises.
Totaro and Raper [22] have shown that 30% of pa-
tients receiving epinephrine after cardiac surgery devel-
oped lactic acidosis but that plasma lactate remained
unchanged in patients who received norepinephrine.
Comparably, small observational studies and case re-
ports have shown an association between epinephrine
use and hyperlactatemia [23]. A small randomized trial
in cardiac surgery patients with postoperative low-
cardiac output syndrome revealed significantly increased
glucose and lactate levels and an increased lactate-
pyruvate ratio in patients who received epinephrine in
comparison with milrinone treatment, suggesting that
epinephrine not only stimulated glycogenesis but also
led to a situation with tissue malperfusion and anaerobic
metabolism despite improved haemodynamics [24]. In
line with this, Levy et al. [25] have shown that muscle
tissue is a major source of lactate in patients with sepsis
during treatment with epinephrine. The authors showed
that patients with septic shock had increased skeletal
muscle lactate production and that these metabolic alter-
ations could be blocked by the Na+/K+-ATPase blocker
ouabain, suggesting that the increased lactate levels were
of a metabolic nature. Nonetheless, the lower oxygen ex-
traction in the high ScvO2 group clearly suggeststhat—besides the metabolic effects of the infused cate-
cholamines—tissue hypoperfusion may be another im-
portant component explaining the significantly increased
rate of organ dysfunction and the higher mortality.
The concept of venous saturation monitoring to guide
haemodynamic therapy is neither new nor peculiar. The
first reports that used venous saturation monitoring to
guide therapy in critically ill patients date back to the
last century [26]. Accordingly, several reviews on this
topic have been published in recent years [8,9] and con-
cluded that venous saturation measurements may be
used to monitor the adequacy of the circulation and to
guide haemodynamic therapy in the perioperative period
[4]. Venous saturation depends on the balance between
oxygen delivery with its covariates—arterial oxygen sat-
uration, cardiac output, and haemoglobin level—and
oxygen consumption. With some limitations, ScvO2 can
be used as a substitute for SvO2 [8,10]. In clinical prac-
tice, ScvO2 is often measured as the use of pulmonary ar-
terial catheters in the context of critical illness; surgery
has declined over the last decade [27].
Studies using venous saturation as a goal to optimize
patients in the ICU reported beneficial results. In the land-
mark study by Rivers et al., performed in patients with se-
vere sepsis and septic shock, this concept has been shown
to decrease mortality in the patient group undergoing a
treatment algorithm aiming for an ScvO2 of at least 70%
[28]. Another study in a cardiac surgery patient population
reported a decreased overall complication rate in patients
optimized to an SvO2 of at least 70% and lactate below
2.0 mmol/L during ICU treatment after surgery [29]. In
that study, patients of the protocol group had a shorter
length of stay in the hospital and overall morbidity was
lower by the time of hospital discharge.
In older as well as in recent studies, low ScvO2 and
SvO2 were linked to unfavourable outcomes [11-13,30].
Thus, our finding of unfavourable outcomes in patients
with ScvO2 below 60% is in line with previous reports. A
study by Perz et al. investigated venous saturation mea-
surements after cardiac surgery [13], indicating that an
ScvO2 below 60.8% in patients undergoing cardiac sur-
gery was associated with an unfavourable outcome.
Table 5 Multivariate Cox regression analysis for short- and long-term survival
Cox regression for in-hospital survival Cox regression for 3-year follow-up survival
HR unadjusted HR adjusted HR unadjusted HR adjusted
Group L, ScvO2 < 60 1.377 (0.905–2.096), 2.124 (0.985–4.582), 1.126 (0.911–1.392), 1.209 (0.893–1.638),
P = 0.135 P = 0.055 P = 0272 P = 0.220
Group H, ScvO2 > 80 1.709 (1.244–2.348), 2.787 (1.565–4.964), 1.462 (1.244–1.718), 1.314 (1.033–1.672),
P = 0.001 P <0.001 P <0.001 P = 0.026
Age in years 1.039 (1.023–1.056), 1.096 (1.056–1.138), 1.050 (1.041–1.058), 1.044 (1.029–1.059),
P <0.001 P <0.001 P <0.001 P <0.001
Type of surgery: valves 1.480 (1.083–2.022), 1.858 (0.991–3.458), 1.596 (1.369–1.860), 1.438 (1.124–1.840),
P = 0.014 P = 0.054 P <0.001 P = 0.004
Type of surgery: CABG + valves 1.469 (0.978–2.207), 1.747 (0.846–3.608), 1.835 (1.519–2.218), 1.281 (0.961–1.703),
P = 0.064 P = 0.132 P <0.001 P = 0.088
Duration of surgery, minutes 1.003 (1.002–1.004), 1.002 (1.001–1.004),
P <0.001 P = 0.010
Pre–operative ACEF score 2.609 (2.232–3.050), 1.379 (1.124–1.693),
P <0.001 P = 0.002
APACHE II score on ICU admission 1.049 (1.039–1.060), 1.030 (1.014–1.047),
P <0.001 P <0.001
TISS score on ICU admission 1.088 (1.069–1.107), 1.100 (1.060–1.142), 1.056 (1.045–1.068), 1.028 (1.009–1.047),
P <0.001 P <0.001 P <0.001 P = 0.004
Atrial fibrillation 2.147 (1.869–2.466), 1.674 (1.340–2.091),
P <0.001 P <0.001
COPD 1.798 (1.538–2.102), 1.497 (1.173–1.910),
P <0.001 P = 0.001
Diabetes mellitus 1.440 (1.070–1.939), 2.076 (1.173–3.675), 1.735 (1.512–1.990), 1.405 (1.137–1.736),
P = 0.016 P = 0.012 P <0.001 P = 0.002
Peripheral vascular disease 1.485 (1.100–2.006), 1.835 (1.064–3.164), 1.865 (1.601–2.174), 1.733 (1.364–2.201),
P = 0.010 P = 0.029 P <0.001 P <0.001
Dobutamine, cumulative dosage mg/24 hours 0.999 (0.998–0.999), 0.999 (0.999–1.000),
P <0.001 P = 0.098
Enoximone, cumulative dosage mg/24 hours 1.000 (1.000–1.000), 0.999 (0.998–1.000),
P = 0.002 P = 0.144
Norepinephrine, cumulative dosage mg/24 hours 1.014 (1.012–1.017), 1.018 (1.011–1.024), 1.015 (1.012–1.017), 1.016 (1.011–1.021),
P <0.001 P <0.001 P <0.001 P <0.001
Values are presented as median (interquartile range). Hazard ratios (HRs) are adjusted for all pre-operative variables, intensive care unit (ICU) admission scores,
and cumulative dosages (first 24 hours in ICU) of inotropic drugs that were significant in univariate Cox regression. Variables have been selected by using stepwise
backward selection. Reference for type of surgery: coronary artery bypass graft (CABG); for grouping variable: group N (60 ≤ ScvO2 ≤ 80). ACEF, Age, Creatinine, and
Ejection Fraction; APACHE II, Acute Physiology And Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease; H, high; L, low; ScvO2, central
venous saturation; TISS, Therapeutic Intervention Scoring System.
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cutoff may carry some risks that lie within the physi-
ology of venous saturations. Our finding of increased
mortality and complication rate in patients with ScvO2
above 80% accords with smaller reports from critically ill
patients and from patients after cardiac surgery.
Pope et al. reported data from 619 emergency depart-
ment (ED) patients. In regard to the maximum ScvO2during treatment in the ED, mortality rates of both the
hypoxia group (40%) and the hyperoxia group (34%)
were significantly higher than the rate of mortality in the
normoxia group (21%) [11]. Therefore, in line with our
results in cardiac surgery patients, central venous hyper-
oxia in ED patients with suspected sepsis seems to be
associated with unfavourable outcomes as well. Yet an-
other study provided evidence that hyperoxia in patients
Figure 3 Kaplan-Meier curves for long-term survival (3-year follow-up) of groups L (ScvO2 < 60%), N (60% ≤ ScvO2 ≤ 80%), and H
(ScvO2 > 80%). Only patients with a minimal observation period of 3 years were included. Patients from groups N and H differed significantly in
pair-wise testing (log-rank test: P <0.001). H, high; L, low; N, normal; ScvO2, central venous saturation.
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That study retrospectively analysed data from all ICU
admissions of patients with septic shock and reported
the maximum ScvO2 within the first 72 hours after the
onset of shock. In conclusion, high levels of ScvO2 (more
than 80%) in the first 72 hours after resuscitating pa-
tients in septic shock were associated with increased
mortality which might reflect an impaired use of oxygen
as evidenced by increased lactate levels [12].
Limitations
Owing to the retrospective nature of our data, it is pos-
sible only to report associations and not causality.
Therefore, we can only speculate about possible mecha-
nisms leading to the increased complication and mortal-
ity rate in the group with high venous saturation
measurements after cardiac surgery. Also, we cannot ex-
clude that changes in management between 2006 and
2013 contributed to this finding. One further point of
concern might be that ScvO2 measurements after admis-
sion to the ICU were missing in about one fourth of the
total population. However, this seems negligible as base-
line characteristics of all patients undergoing cardiac
surgery regardless of effectuated ScvO2 measurements
did not differ statistically (data not shown).
Nevertheless, we believe that it is important to provide
evidence that high venous saturation measurementsshould not be misinterpreted as safe but should be con-
sidered to be associated with increased mortality and
complication rates. Additionally, despite the increasing
use of ScvO2 in clinical practice, several lines of evidence
point out that, at least during states of increased oxygen
extraction [10,20], the difference between ScvO2 and
SvO2 may increase. In these situations, ScvO2 levels do
not reliably reflect the ‘true’ systemic balance between
oxygen delivery and demand. Nonetheless, with respect
to the frequent use of ScvO2 in routine practice [27] and
current recommendations for the use of ScvO2 for titrat-
ing haemodynamic therapy in cardiac surgery patients
[6], the findings of the present study have relevant prac-
tical implications.
Conclusions
We demonstrated that patients after cardiac surgery pre-
senting with an initial ScvO2 higher than 80% on ICU
admission—which might be considered safe or even
optimal—had the highest in-hospital mortality and high-
est mortality in 3-year follow-up. This group also had in-
creased lengths of ICU and hospital stay, increased
mechanical ventilation after surgery, and increased rates
of postoperative renal dysfunction and failure. Increased
inflammation markers in patients with an initial ScvO2
higher than 80% might point to a postoperative ‘sepsis-
like’ syndrome with oxygen extraction dysfunction.
Balzer et al. Critical Care  (2015) 19:168 Page 11 of 12Therefore, it seems indicated that additional advanced
haemodynamic monitoring may help to identify patients
with high ScvO2 who developed extraction dysfunction
and to establish treatment algorithms in order to im-
prove outcome.
Key messages
 In this study, we describe a statistically significant
association between an initial ScvO2 higher than 80%
on ICU admission after cardiac surgery and an
increased in-hospital and 3-year follow-up mortality.
 Additional haemodynamic monitoring may help to
identify patients with high ScvO2 who developed oxygen
extraction dysfunction and to establish treatment
algorithms in these patients to improve outcome.
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